New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion - Drugs.com MedNews
Links shared publicly online about this topic.
- 603total visits
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion - Drugs.com MedNews
Data from largest cardioversion analysis to date show low frequency of stroke and major bleeding with Pradaxa Results of a post-hoc analysis of the RE-LY trial
View full resource at drugs.com
Tags: Heart Disease, Arrhythmia, Atrial Fibrillation, Bleeding, Stroke, Thrombotic Event, Drug
Most Recently Shared on January 5, 2011 at 3:16 pm By:
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardiover... http://bit.ly/eT8aVr #drug
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion
medicalnewstoday.com — “Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to no” View full resource at medicalnewstoday.com
Most Recently Shared on January 6, 2011 at 4:56 pm By:
MNT Cardiovascular Health News
New Sub-Analysis Of RE-LY Trial Examines Pradaxa In Patients With Atrial Fibrillation Undergoing Cardioversion http://mnt.to/3PHb
Advertisement
